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Summary
Decay-accelerating factor (DAF) is a glycosyl-phosphatidylinositol (GPI)-anchored membrane
protein that protects cells from complement-mediated damage by regulation of the C3 convertase.
To investigate the role of the GPI anchor in the function of DAF, the cDNA encoding human
DAF was expressed by transfection in Chinese hamster ovary (CHO) cells. Testing of these DAF
transfectants in an antibody plus human complement-mediated cytotoxicity assay demonstrated
that DAF protects these cells from cytotoxicity, and that the level of protection increases with
expression ofsurface DAE A cDNA construct encoding a transmembrane version ofDAF (DAFTM)
protects CHO transfectants from cytotoxicity with equal efficiency to DAF. This DAFTM construct
used the TM and cytoplasmic domains of membrane cofactor protein (MCP); an alternate TM
version ofDAF constructed with the TM and cytoplasmic domains of HLAB44 showed equivalent
protection. The protection from cytotoxicity involved a decrease in the deposition of C3 on the
cell, consistent with the effect of DAF on the C3 convertase. A second pair of anchor variants,
MCP and a GPI-anchored construct, MCP-PI, were also equivalent in their complement protection.
The equivalent function ofGPI-anchored and TM versions of a protein was not expected based
on the hypothesized increased lateral mobility of GPI-anchored proteins, which should confer
a functional advantage in contacting ligand, in this case, C3b or C4b, on the cell surface. These
data suggest either that GPI-anchored and TM versions of a protein have equal lateral mobility
in the membrane, or else that increased lateral mobility is not advantageous to DAF or MCP
in carrying out their complement inhibitory roles. Furthermore, DAF and MCP demonstrated
approximately equal protection ofcellsfrom complement-mediated cytotoxicity, suggesting that
DAF and MCP provide overlapping levels of protection to cells against damage mediated by
the complement system .
T
issues are subject to inflammatory damage mediated by
the complement (C) system. To keep this pathway in
check, multiple control proteins downregulate the action of
C. The largest group of control proteins is the regulators
of complement activation (RCA)' multigene family on the
long arm of chromosome 1(1), including the membrane pro-
teins C3b receptor (CRI), Cad receptor (CR2), decay-acceler-
ating factor (DAF), and membrane cofactor protein (MCP),
as well as the serum proteins factor H and C4-binding pro-
tein, all of which function at the critical C3 convertase step.
CR1 and CR2 have limited distribution on hematopoietic
'Abbreviations used in this paper: DAF, decay-accelerating factor; GPI,
glycosyl-phosphatidylinositol; HRF, homologous restriction factor; MCP,
membrane cofactor protein; MIRL, membrane inhibitor of reactive lysis;
RCA, regulators of complement activation; TM, transmembrane.
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cells (2), and CR1 appears to function mainly extrinsically
to the cell where it resides (3), so these proteins do not ap-
pear to be the major elements protecting individual cells from
C. On the other hand, DAF and MCP (reviewed in reference
4) are widely distributed on hematopoietic cells and on en-
dothelial and epithelialtissues (5-10), and DAF functions in-
trinsically to protect cells from complement (11), suggesting
that DAF and MCP might be the most important general
elements of the RCA multigene family for protecting cells
from complement-mediated damage. Another set of regula-
tory proteins, homologous restriction factor (HRF) (alsocalled
C8-binding factor) (12, 13) and membrane inhibitor of reac-
tive lysis (MIRL) (also called HRF20) (14-17), both inhibit
at the C8/C9 stage of the membrane attack complex.
Interestingly, DAF, HRF, and MIRL are all glycosyl-
phosphatidylinositol (GPI)-anchored membrane proteins (15,
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Volume 174 July 1991 35-4417-23). Oneoftheproposed properties of GPI-anchored mem-
braneproteins is an increasedlateral mobility compared with
transmembrane (TM) polypeptide-anchored membrane pro-
teins. Specific measurements for DAF (24) and Thy-1 (25)
have shown these two GPI-anchored proteins to have lateral
diffusionconstantsmore in the typical higher rangeof mem-
brane lipids than of TM proteins. It has been hypothesized
that the GPI anchor permitsfaster mobility in themembrane
and produces an advantageto theprotein in carrying out its
function. In the case of the GPI-anchored C proteins, the
proposed faster lateralmobility wouldpermit more rapid con-
tact of theregulatory protein with the C components to which
it is targeted, i.e., DAF to C3b/C4b, and HRF and MIRL
to C8/C9. There is no direct evidence, however, for this
proposal.
In the present study, we demonstrate directly that GPI-
anchored and TM versions of DAF or MCP protect cells
equallywell from C3 deposition andcytotoxicity. To accom-
plish this we have established transfected Chinese hamster
ovary (CHO) cell lines expressing DAFor MCP, andshown
that thetransfected humangene products protect foreigncells
from human complement.
Materials and Methods
Antibodies.
￿
A rabbit polyclonal antibody to human DAF was
prepared as described (26). F(ab')2 was prepared from this antibody
by digestion with immobilized pepsin (27) followed by a protein
A-Sepharose column to remove F, fragments and any undigested
IgG, accordingto manufacturer's directions (PierceChemical Co.,
Rockford, IL). The murine mAbs to humanDAF IA10 and IIH6
(5) were generously provided by T Kinoshita (Osaka University,
Osaka, Japan), and the mAb 1C6 (28) to DAF was a gift from
T Fujita (Fukushima Medical College, Fukushima, Japan). Mu-
rine mAb E4.3 (29) to human MCP was a gift from D. Purcell
and 1. McKenzie (University of Melbourne, Melbourne, Australia).
Murine mAbto human C3cwaspurchasedfrom Quidel (San Diego,
CA), andisotype control (IgGl) mAbwaspurchasedfrom Accurate
Chem. & Sci. Corp. (Westbury, NY). Rabbit polyclonal antibody
to hamsterPBL (which crossreacts with CHO cells) wasobtained
from Accurate Chem. & Sci. Corp. (Westbury, NY), and another
rabbit polyclonal antibody was produced by immunization with
CHO cells.
DNA.
￿
We have reported full-length cDNA for DAF (30, 31)
and MCP (32). cDNA constructs representing a TM version of
DAFand aGPI-anchored version ofMCPwere madeby exchanging
theregions of thecDNAs encoding the COON-terminal domains
of each protein using standard techniques of restriction enzyme
digestion, isolation ofDNAfragments from agarose gels, andsub-
sequent ligation (33). Specifically, DAFTMconsists of aminoacids
1-304 ofDAFand270-350ofMCP, andMCP-P1 consists ofamino
acids 1-269of MCPand307-347of DAF(numbering starts from
the first amino acid of the mature protein without the signal pep-
tide). An alternate construct for a TM version of DAF using the
TM andcytoplasmic domains of HLA-B44 hasbeen reported (34).
To confirmin-frame ligation,allconstructs were sequencedthrough
the region of the splice using double-stranded DNA (35) and Se-
quenase (36). The expression vector SFFVneo (37), which con-
tains thespleen focus-forming virus 5' long terminal repeat,SV40
splicing and polyadenylation signals, and the neomycin-resistance
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gene, was a gift from S. Fine and D. Loh (Washington University,
St. Louis, MO).
Expression ofcDNA.
￿
Full-length cDNA forexpression was sub-
cloned into theEcoRI site of SFFV.neo (using EcoRIlinkerswhere
necessary). This DNA was transfected into CHO cells by lipid-
mediated DNAtransfection with 101AgDNAand 100jigLipofectin
(38). CHO cellswere maintained in Ham's F12medium, 5% FCS,
2 mM glutamine, 100 U/ml penicillin, 100 p.g/ml streptomycin
in an atmosphere of humidified 5% C02, 95% air at 37°C. Posi-
tive cellswere selected by resistance to theneomycin analogue G418
(0.25 mg/ml active drug). These selected cellswere then subjected
to avariable number of rounds of sterile sorting by flow cytometry
(Epics V, Coulter Immunology, Hialeah, FL) using either rabbit
polyclonal antibody to DAFor murine mAb E4.3 to MCP as pri-
mary antibodies andappropriate FITC-labeled second antibody.In-
dividual subclones were produced by limiting dilution.
Biosynthetic Labeling and Immunoprecipitation.
￿
Transfected CHO
cells were biosynthetically labeled with ["S]cysteine (>1,000
Ci/mmol). Cells at -70% confluence in 100-mm tissue culture
plates were washed andplaced in cysteine-free medium (cysteine-
free Ham's F12 medium, 5% dialyzed FCS, 2mM glutamine, anti-
biotics) for 1 h, after which ['sS]cysteine was added to 100
p,Ci/ml, andincubation continuedfor 4 h. After labeling, the su-
pernatantwasremoved, cells were washed twiceat 4°C with Tris-
buffered saline (10 mM Tris, 150 mM NaCl, pH 7.4), and then
the cells were solubilized in a1% solution ofTriton X-114 in Tris-
buffered saline in the presence of the protease inhibitors aprotinin
(100 U/ml), PMSF (2 mM), and pepstatin (1 ttM). The nonionic
detergent Triton X-114 has been used to isolate membrane pro-
teins, forit has the useful property that above thecloudpoint tem-
perature of N20°C, thesolution separates into detergent-rich and
detergent-poor or aqueous phases, with integral membrane pro-
teins partitioning into the detergent phase (39). The Triton X-114
detergent phaseof thecell lysate was immunoprecipitated with ei-
ther anti-DAF or anti-MCP antibodies using Staphylococcus aureus
Cowan I strain as an immunosorbent as previously reported (40).
Samples were analyzedby SDS-PAGE on 9% acrylamide gels under
reducing conditions followed by fluorography as described (40).
Assay for GPI Anchor.
￿
Cells were labeled as described above,
and the solubilized membrane proteins (fromthe Triton X-114de-
tergent phase) were treatedwith 0.2 UPI-PLC from Bacillus thurin-
giensis (a gift from M. Low, Columbia University, NewYork, NY)
or control buffer at 15°C for 16'h, then separated into detergent
and aqueous phases, immunoprecipitated, and analyzed by SDS-
PAGE. In some cases, membrane proteins were immunoprecipi-
tatedbefore PI-PLC treatment, whichwas then carriedoutat 23 °C
for 4-16 h. A GPI anchor was indicated by the ability of PI-PLC
to release the protein from the detergent phase to the aqueous
phase (41).
Flow Cytometry.
￿
1-2 x 106 transfected cells were washed and
incubatedwith saturating concentrations ofrabbit polyclonal anti-
body to DAF or murine mAb to MCP for 30 min at 4°C, then
washed andstained with appropriate FITC-labeled second antibody
for 30 min at 4°C. In some cases, murine mAb to DAF was used.
10° cells were then analyzed on a FACScan® (Becton Dickinson
& Co., Mountain View, CA) flow cytometer to assess surface ex-
pression ofDAFor MCP. Quantitative comparison ofmean channel
fluorescence wasused to assess relative expression of DAF or MCP,
usingone DAF or one MCP transfectant as an arbitrary standard.
In some cases, an approximate comparison of the DAF and MCP
scales was made by performing flow cytometric analysis oftheDAF
and MCP standards using IA10 mAb for DAF and E4.3 mAb for
MCP, respectively. Both of these mAbs are subclass IgG2a, andthe same FITC-labeled anti-mouse IgG was used for both cells,
allowing a semi-quantitative comparison of theDAFandMCPex-
pression levels.
s1Cr Release Cytotoxicity Assay.
￿
CHO cells were plated at 1.6
x 10° per well in 96-well trays 1 dbefore the assay. On the next
morning, the cells were labeled with "Cr by incubation with 2
FtCi per well in complete medium for 3 h at 37°C. Wells were
then washed, 25 ul rabbit antiserum or dilution was added, and
the plates were incubatedon ice for30 min . Then, 100 ul of human
C (or dilution) was added, and the plates were incubated at 37°C
for 60 min. 100 Al of supernatant was removed from each well
and counted for radioactivity. Cells incubated without antibody
orC (control) were used to measure spontaneous 5'Cr release, and
cells incubated with 1% SDS were used to measure complete re-
lease . Specific percent "Cr release (cytotoxicity) was calculated as :
(test cpm - controlcpm)/(SDScpm - controlcpm) . All samples
were done in quadruplicate, and the SEM for cytotoxicitywas1-5% .
In some experiments, DAF function wasblockedby preincuba-
tion with antibodies . Specifically, after 51Cr labeling, the cells were
incubated with 25 p,l 1C6DAF mAb, which has been shown to
blockDAFfunction (28), or subclass control mAbMOPC21 (mu-
rine IgG1 subclass antibodies do not activate C) . After incubation
on ice for 30 min, the remainder of the cytotoxicity assay was car-
ried out as detailed above . A similar blocking wasdone with rabbit
polyclonal anti-DAF F(ab')z or normal rabbit IgG F(ab') 2 .
C3 Deposition on Cells.
￿
C3 deposition on cells by the action
ofantibody andC wasmeasured essentially as described (42) . Briefly,
CHO transfectants were removed from tissue culture plates by brief
trypsinization . After washing, the cells were treated with rabbit
antibody and human C as in the "Cr release cytotoxicity assay.
At thecompletion ofthose incubations, the cells were washed and
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sequentially incubated with murine mAb to C3c or subclass con-
trol MOPC21 and FITC-labeled anti-mouse IgG, then analyzed
by flow cytometry.
Results
Creation ofCHO Transfectants Expressing DAF as GPI-
anchored or Transmembrane Protein . To be able to compare
the protein with alternate modes ofmembrane attachment,
we constructed aversion ofDAF with the COON-terminal
domain replaced by theTM andcytoplasmic domains ofMCP
ThiscDNA construct, designated DAFTM, andDAF were
subcloned into the expression vector SFFVneo (37), trans-
fected into CHO cells with lipofectin (38), and selected in
G418 . To demonstrate the mode of membrane attachment
of the transfected proteins, the susceptibility to PI-PLC was
tested : PI-PLC releases GPI-anchored proteins from the de-
tergent to the aqueous phase of Triton X-114 by removing
the di(acyl/alkyl)glycerol moiety that forms the membrane
(or detergent) binding domain of the protein. For this assay
the cells are biosynthetically labeled with [35S]cysteine, ex-
tracted in Triton X-114, treatedwith PI-PLC or buffer, phase
partitioned, immunoprecipitated with antibodies to DAF, and
analyzed by SDS-PAGE and fluorography. The transfected
DAF in CHO cells repartitions into the aqueous phase of
Triton X-114 afterPI-PLC treatment (Fig. 1A),whereasDAF-
TM is unaffected by PI-PLC treatment in this assay (Fig. 1
B), demonstrating the GPI anchoring ofDAF and the TM
anchoring of DAFTM.
Figure 1 .
￿
Expression of DAF as a
GPI-anchored orTM protein inCHO
cells. CHO cells were transfected with
the expression vector SFFV.neo con-
taining thecDNA forDAF or thecon-
struct DAFTM, wheretheCOOH ter-
minus ofDAF is replaced with theTM
and cytoplasmic domains of MCP .
Pooled transfectantswere selected in the
neomycin analog G418 . Stable transfec-
tants were assayedfor the form of mem-
brane anchor of DAF by biosynthetic
labeling with [sSS]cysteine, digestion of
the Triton X-114 detergent extract with
PI-PLC or controlbuffer, phase separa-
tion, immunoprecipitation with anti-
DAF antibody, followed by SDS-PAGE
and fluorography. The presence (+) or
absence (-) ofPI-PLC digestion of the
sample and the Triton X-114 detergent
(D) or aqueous (A) phase are shown
above the lanes. (A)DAF ; (B)DAFTM .m
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Figure 2.
￿
Transfectants that express a range of levels of DAR Pooled
stable transfectants for DAF were sorted for high DAF expression by flow
cytometry and cloned by limiting dilution. Individual clones were ana-
lyzed by flow cytometry using arabbit polyclonal antibody to human DAR
Three representative clones are shown in this figure, one from a cell trans-
fected with vector alone (SFFV) to serve as a negative control for im-
munofluorescence and two individual clones transfected with DAR
We next wanted to create a set of transfectant clones that
expressed a range of DAF levels. The pooled transfectants
were sorted for high DAF expression byflow cytometry and
cloned by limiting dilution. Individual clones were analyzed
by flow cytometry and demonstrated a range of expression
(two representative DAF clones are shown in Fig. 2).
DAF Protects CHO Transfectants from C-mediated Cytotox-
icity. To study the function of the transfected DAF mole-
cule, the CHO transfectants were tested in a "Cr release cy-
totoxicity assay that used a rabbit polyclonal antibody (raised
against hamster lymphocytes) and human C. Several control
CHO transfectants (SFFV vector only) were lysed, whereas
a CHO transfectant expressing DAF was almost completely
protected from cytotoxicity (Fig. 3 A) . Controls involving
antibody or C alone showed that both were required for lysis.
Inactivation of the human C at 56°C for 30 min to destroy
both C pathways abrogated all cytotoxicity, and inactivation
of the human C at 50°C for 20 min to destroy the alternate
pathway ofC demonstrated that this was a classical pathway-
mediated event, as expected for an antibody-initiated process
(data not shown).
A second rabbit polyclonal antibody that was raised against
CHO cells was tested in the cytotoxicity assay, and the DAF
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Figure 3. Transfected DAF protects
CHO cells from antibody plus C-mediated
cytotoxicity. A CHO cell line transfected
withDAF was compared with several con-
trol cell lines transfected with SFFV vector
alone, using a rabbit antibody plus human
C 51Cr release cytotoxicity assay, as de-
scribed in Materials and Methods. (A) The
results ofthe cytotoxicity assay show a titra-
tion curve of percent cytotoxicity vs. anti-
Antibody Dilution
￿
bodydilution. The rabbit polyclonal antibody
was raised against hamster lymphocytes.
Two clones from CHO cells transfected with vector alone (SFFV) are shown, along with the pool of cells from the SFFV transfection and a clone
from the CHO cells transfected with DAR The assay is done in quadruplicate, and SEM ranges from 1% to 5%. DAF clearly protects the cells from
cytotoxicity compared with any of the control transfectants. (B) Cytotoxicity assay comparing one of the DAF and control (SFFV) clones using a
rabbit antibody raised against CHO cells, again demonstrating the protective effect of transfected DAR
_cell
O SFFV/8G
" DAF/F12
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Cell DAF
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Figure 4.
￿
Dose-response effect of transfected DAF in protecting cells
from cytotoxicity. A set ofDAF clones that express a range ofDAF (levels
shown in the inset in the figure, with the DAF expression determined
by flow cytometry, as in Fig. 2, relative to clone DAF/F12 arbitrarily set
to 100 U) was tested in the 51Cr release cytotoxicity assay, as described
in the legend to Fig. 3.
transfectants were also relativelyprotected from C-mediated
cytotoxicity (Fig. 3 B). This antibody had a higher titer than
the previous antibody (compare Fig. 3, A and B). The de-
gree of protection, although not as complete as with the
previous antibody, was still quite marked (Fig. 3 B), and pro-
vides evidence that this finding is not limited to any specific
antibody.
Glycophospholipid-anchored and Transmembrane Versions ofDAF
Protect Cells Equally Wellfrom C-mediated Cytotoxicity. The
data (Fig. 3) demonstrate that the CHO cells transfected with
DAF are protected from C-mediated cytotoxicity. This pro-
vides a system for testing mutations in DAF to assess the
effect of the variation on function. Specifically, we address
the question ofwhether the GPI anchor of DAF confers any
functional advantage (or disadvantage) over a polypeptide TM
anchor. To compare the functional efficiency of the two ver-
sions ofDAF, we established a set of CHO transfectants ex-
pressing a range of levels of DAF or DAFTM. The relative
level ofDAF expression on any clone was quantitated byflow
cytometry (see Fig. 2 as a representative example) using one
DAF clone as a standard, arbitrarily designated as 100 U. The
surface expression was assessed with a rabbit polyclonal anti-1:1 1:2 1:4 1:8 1:16 1:32
Antibody Dilution
Figure 5.
￿
Transfected DAFTM has an equivalent effect to DAF in pro-
tecting cells from C. A set ofDAFTM clones that express the same range
of DAF levels as the set of DAF transfectants in Fig. 4 was tested in the
cytotoxicity assay, as described in the legend to Fig. 3. A single DAF trans-
fectant clone was also run in this assay for comparison. Although there
was a small assay-to-assay variation in the level of cytotoxicity (compare
the maximum 91% cytotoxicityofclone SFFV/8Gin Fig. 4 with the max-
imum 64% cytotoxicity of the same clone in Fig. 5), the overall dose-
response effect of increasing protection with increasing DAF expression
was similar andcovered the same quantitative range for the DAFTM clones
as for the DAF clones tested in Fig. 4.
DAF However, because of concern that the alternative modes
of membrane anchoring might affect the binding of antibody
to some epitopes, the quantitation was repeated with anti-
DAF mAbs 1A10 and I1H6 (5), and both mAbs gave the same
quantitation as the polyclonal antibody (data not shown).
A set of DAF clones was then tested in the antibody plus
C cytotoxicity assay. There is a clear dose-response relation-
ship between the expression of transfected DAF in a clone
and the amount ofprotection from cytotoxicity (Fig. 4). This
finding in itself provides additional support for the conclu-
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Figure 6.
￿
Equivalent cytotoxicity protection ofDAF and DAFTM seen
under conditions oflimiting C dilution. The previous cytotoxicity assays
all used antibody dilutions and full-strength C. To compare the two ver-
sions of DAF under conditions oflimiting C, the cytotoxicity assay was
performed as a C dilution, with all other procedures are as described in
the legend to Fig. 3. A low and a high expression DAF/DAFTM pair
were both tested in this cytotoxicity assay, and again demonstrated the
equivalent protective effect ofDAF and DAFTM under these conditions
of limiting C.
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Figure 7.
￿
An alternate TM version of DAF is also equivalent to GPI-
anchored DAF in its C-protective effect. The DAFTM construct tested
above uses the TM and cytoplasmic domains ofMCP. An alternate DAF-
TM was constructed with theTM andcytoplasmic domains ofHLA-B44.
This was expressed in CHO as described in thelegend to Fig. 1, and tested
by the cytotoxicity assay as described in the legend to Fig. 3. A clone ex-
pressing the DAF-TM(HLA) construct was compared with clones expressing
DAF, and it falls right on the same dose-response curve of cytotoxicity
protection as DAR
sion that the protection from cytotoxicity is specifically caused
by the transfected DAR When a set of DAFTM clones
covering a similar range of DAF expression was surveyed,
they showed an equivalent dose-response relationship (Fig.
5). These assays using undiluted C and a range of antibody
dilutions represent conditions of limiting antibody. Reasoning
that subtle differences in protection might be more apparent
under conditions of limiting C, the cytotoxicity assay was
also run under these conditions. The same equivalent efficiency
ofDAF and DAFTMin protecting the cells from C-mediated
cytotoxicity was seen (Fig. 6). Thus, versions of DAF with
either a GPI or a TM anchor demonstrate equal efficiency
in protecting the cell from C-mediated cytotoxicity.
A second TM version of DAF, which uses the TM and
cytoplasmic domains of HLAB44 (34) instead ofMCP, was
also tested. A transfectant expressing this alternate DAFTM
was protected from C-mediated cytotoxicity, with the de-
gree of protection falling right on the DAF-response curve
(Fig. 7). Therefore, the equivalence of the GPI and TM an-
chors for DAF in the protection from C-mediated cytotox-
icity does not appear to vary with different TM anchors.
Protection from C-mediated Cytotoxicity Conferred by Trans-
fected DAFInvolves DAFFunctional Domain andResults in De-
creased C3 Deposition. All of the data on cytotoxicity involve
the end result of C damage to the cell by the membrane at-
tack complex. DAF functions to regulate the C cascade by
its inhibitory action on the C3 convertase (43), which then
has the downstream effect of decreasing the overall level of
cytotoxicity. The next set of experiments were designed to
confirm that the protective effect seen in DAF transfectants
does in fact involve the functional domain ofDAR The first
approach was to block the DAF functional site with anti-
bodies and demonstrate reversal ofthe protection. Specifically,
the transfectants were preincubated with blocking antibodies
before addition ofthe rabbit antibody and human C. pretreat-
Cell DAF
100
O SFFV/8G 0 80 o DAF-TM/6C 38
DAF-TM/6B 75
DAFIF12 100 60
A DAF-TM/2H 97 vFigure 8 . Blocking DAF functional domain with antibody reverses
C-protective effect oftransfectedDAF and DAF-TM .A vectorcontrol-trans-
fectedclone (SFFV/8G), clone DAF/F12, and clone DAF-TM/2H (the latter
two clones expressing equal amounts of surface DAF) were tested in the
s'C r release cytotoxicity assay, as described in the legend to Fig . 3, with
the following addition: the cells were pretreated with anti-DAF blocking
antibody or isotype control, as indicated in the graph inset, for 30 min
at 4°C beforebeing incubated with rabbit antibody and human C . Blocking
with either mAb 1C6 or F(ab')Z rabbit anti-DAF reverses the protection
from cytotoxicity afforded by the transfectedDAF with either GPI orTM
anchor .
ment of theDAF or DAFTM transfectants with DAF mAb
1C6, which blocks DAF function (28), led to reversal of the
protective effect ofthe TansfectedDAF (Fig. 8) . Control mAb
MOPC21 of the same subclass had no effect, and the mAbs
had no effect on theSFFV (vector only control) transfectant .
Similarly, rabbit polyclonal anti-DAF F(ab')z, but not con-
trol rabbit IgG F(ab')2, also reversed the protective effect of
the transfected DAF (Fig . 8) .
Next, toshow that the transfectedDAF is actually having
an effect on C3 deposition, we measured C3 levels on the
cells. Transfectants were treated with rabbit antibody and
human C as in the cytotoxicity protocol (omitting the SICr
labeling), and they were then analyzed by flow cytometry
for surfaceC3 expression using amAb against C3c. TheDAF
and DAFTM clones tested had equal DAF expression, and
this resulted in equal reductions in C3 deposition compared
with the control SFFV transfectant (Fig. 9) . Thus, the pro-
tective effect of the transfected DAF is specific for the DAF
functional domain and results in decreased C3 deposition .
GPI-anchored and Transmembrane Versions ofMCP Show
Equivalent Protective E$ect against C-mediated Cytotoxicity . To
generalize the present finding that DAF functions equiva-
lently in inhibiting the C cascade whether anchored by a GPI
or TM structure, we tested another pair of anchor variants.
The purified membrane protein MCP has cofactor activity
for the factor I-mediated proteolysis ofCab and C4b when
assayed in the fluid phase (44), and it is presumed that the
intrinsic membrane protein has similar activity and thus pro-
tects the cell from C damage . MCP is a TM protein ; we con-
structed a variant ofMCP that is GPI anchored by replacing
the region of the MCP cDNA that encodes the TM and cy-
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Figure 9 .
￿
Protection from cytotoxicity of cells transfected with DAF
orDAFTM is marked by reduced C3 deposition . The clones SFFV/8G,
DAF/F12, andDAFTM/2H (same clones as used in Fig . 8) were briefly
trypsinized from plates, then treated exactly as in the cytotoxicity assay
outlined in the legend to Fig. 3, except there was no s 1Cr labeling step.
After the rabbit antibody and human C incubation steps, the cells were
washed and treated sequentially with mousemAb against human C3c or
isotype controlMOPC21 followed by FITC-labeled goat anti-mouse IgG,
and then analyzed for fluorescence by flow cytometry. SFFV cells treated
with MOPC21 give the background immunofluorescence .
toplasmic domains with the region of the DAF cDNA that
encodes theCOOH-terminal signal for GPI anchor addition .
Testing ofCHO transfectants expressing these two versions
ofMCP, the wild-type MCP and MCP-PI, with PI-PLC es-
tablished that they do in fact encode membrane proteins that
use TM and GPI anchors, respectively (Fig. 10) .
Cell sorting followed by limiting dilution cloning was used
to produce clones with a range of surface expression ofMCP,
just as reported above for DAR Transfectants expressing ap-
proximately equal amounts ofMCP or MCP-PI were tested
in the antibody plusC cytotoxicity assay (Fig. 11) . This demon-
strated, first, that MCP does act as an intrinsic C-protective
molecule in the cell membrane, and, second, that it carries
out this function equivalently with either aTM orGPI anchor.
Finally, these results provide a comparison of the C-pro-
tective effect ofDAF vs. MCP. Note that the level of expres-
sion ofMCP is determined by flow cytometry with E4.3 mAb,
with the units ofexpression relative to one arbitrarily selected
clone . However, a reasonably quantitative comparison can be
made between the DAF and MCP transfectants by using a
mAb of the same subclass for each protein together with the
same FITC-labeled goat anti-mouse IgG second antibody.
This was done using theDAF mAb IA10 (5) and the MCP
mAb E4.3 (29), both of the murine IgG2a subclass, and it
showed that theMCP andMCP-PI clones in Fig. 11 had ap-
proximately half as many surface molecules of the transfected
cDNA as the DAF clone . Although these comparisons are
only semi-quantitative, the cytotoxicity assay therefore shows
that the MCP and MCP-PI transfectants had the same ap-
proximate level of protection from C-mediated cytotoxicity
as equivalent DAF transfectants (compare Fig. 4 with Fig.
11) . Thus, these data not only establish that MCP functions
as an intrinsic membrane protein to protect against C-mediated
cytotoxicity with either aTM orGPI anchor, but it suggests
that DAF and MCP are similar in their efficiency for car-
rying out this protection of cells .Discussion
The two main results of this study are the demonstration
that transfected foreign cells expressinghumanDAF or MCP
are protected from C-mediated cytotoxicity, and the finding
that both GPI-anchored as well asTM versions of these pro-
teins function equally well in carrying out this C protection .
The former result confirms the known role ofDAF on the
cell and establishes that MCP can also carry out this C-pro-
tective effect intrinsically on a cell . The latter finding goes
against a hypothesized role for the GPI anchor on a mem-
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Transfected MCP or MCP-PI protect cells equivalently from
C-mediated cytotoxicity . Clones expressing MCP or a GPI-anchored ver-
sion of MCP, MCP-PI, at approximately equal levels were tested in the
cytotoxicity assay, as described in the legend to Fig. 3, along with an SFFV
vector control and a DAF transfectant .
Figure 10 . Expression of MCP as a TM or GPI-
anchored protein in CHO cells . The cDNAs for MCP
or a construct designated MCP-PI where the TM and cy-
toplasmic domains ofMCP are replaced with the000H-
terminal domain ofDAF (which encodes the signal for
GPI anchor attachment) were expressed inCHO cells and
tested for the mode ofmembrane anchoring with PI-PLC .
Protocols and figure labels are described in the legend to
Fig. 1 . (A) MCP; (B) MCP-PI,
brane protein, leaving open the question of what, ifany, ad-
vantage is conveyed by having a GPI anchor on DAR
The study ofthe physiological role ofmembraneDAF and
MCP has been approached at three increasingly specific levels :
(a) functional analysis ofthe purified protein extracted from
themembrane; (b) study of the protein in themembrane using
antibodies to block function; and (c) in the case ofDAF, rein-
corporation of the purified protein into the cell membrane .
These proteins in solution could inhibit the C3 convertases
of either the classical or alternate pathways, DAF by inhibiting
the formation and accelerating the decay of C3 convertases
(43), and MCP by acting as a cofactor for the factor I-medi-
ated proteolytic cleavage ofCab orC4b (44) . That DAF could
carry out this function when present in the membrane of
an intact cell wasshown by blocking the DAF function with
antibody (45) : a cell that naturally expresses DAF could be
compared with the same cell without DAF (DAF function
blocked by antibody) . Three membrane proteins are known
to blockC3 convertase function, CR1, DAF, andMCP CR1,
with a limited tissue distribution, functions extrinsically on
C3 convertases in the fluid phase or on other cells and does
not appear mainly to serve the role ofprotecting the individual
cell where it is located (3) . DAF does function intrinsically
(11) . The function ofMCP on intact cells has not been ex-
plored until recently, although MCP has been hypothesized
to function similarly to DAF in this regard . The antibody
blocking data on DAF was done on human erythrocytes, which
do not possessMCP . There were no cells or cell lines known
that possess MCP but not DAF or CRI, so similar data on
the function ofMCP were not available. While this manu-
script was in preparation, a report by Seya et al . (46) appeared
that identified two suchhumanT cell lines, and studies using
MCPmAb blocking demonstrated that MCP was functioningon the cells to block C. The final and most direct approach
to the function ofthese molecules involves incorporation into
a cell that does not possess them; and for DAF, this was made
possible because of this GPI anchor: the purified molecule
would reincorporate into cells as an integral membrane pro-
tein (11). This made possible direct studies ofcells with and
without DAF and confirmed the function of the molecule
in the plasma membrane (11). This was not possible for TM
molecules such as MCP.
The present model based on transfected cells extends the
ability to study the function of these proteins, essentially
without restriction. The cloned cDNA is expressed by trans-
fection in CHO cells, and then these cells can be tested for
protection from the action ofhuman C. We have shown that
an assay based on antibody plus C functions in this system.
This can involve the overall effect of cytotoxicity (Fig. 3) or
a more specific point in the C pathway such as C3 deposition
(Fig. 9). We have used this system to demonstrate that both
DAF and MCP can protect cells from C (Figs. 4 and 11).
This confirms the results involving DAF reincorporation into
cell membranes (11) and provides the most direct evidence
that MCP functions in a cell membrane as a C-protective
molecule. This model is particularly valuable because of the
ability to study any variant of a molecule. In this report, we
made use ofthis approach to study variants of DAF and MCP
that used alternate membrane anchoring (DAFTM and
MCP-PI). The same methodology can be used to studypoint
mutations or deletions in the cDNA to map structural or
functional domains in the encoded protein (Lublin, D.M.,
manuscript in preparation) .
In this study, we found that DAF and MCP had roughly
equivalent C-protective effects. This conclusion is based on
semi-quantitative comparisons ofthe levels of surface expres-
sion of DAF and MCP by flow cytometry, and it is not to
be interpreted beyond an order-of-magnitude comparison; a
more precise comparison will require quantitative measure-
ments by immunoassay. Another important question for in-
vestigation is whether DAF and MCP, using different mech-
anisms for inhibiting the C3 convertase, can act synergistically,
or do they simply provide a levelofredundancy in protecting
cells.
The finding that both DAF and MCP can be incorporated
into cells and protect them from C has implications for the
possible therapeutic use ofthese C regulatory proteins as im-
munomodulators. Two major points in the C cascade where
regulatory proteins function is at the C3 convertase stage (RCA
family) and at the membrane attack complex stage (HRF and
MIRL). Although the latter group might have a greater di-
rect effect on cytotoxicity, the RCA proteins not only block
cytotoxicity but also block the deposition of C3b/C4b on
the cell (which makes it a target for clearance by CR1-bearing
phagocytic cells) and the release of the anaphylatoxic and
chemotactic C peptides C3a and C5a. In a recent report, a
soluble form ofrecombinant human CR1 was shown to have
antiinflammatory properties in a rat model of reperfusion in-
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jury (47). Soluble forms of DAF and MCP should function
similarly as therapeutic agents in autoimmune and other
inflammatory states; CR1 has the advantage of possessing
both decay-accelerating activity and cofactor activity, but DAF
and MCP together have both C3 convertase inhibitory func-
tions and might offer an advantage due to their three times
smaller MT. However, a potentially much greater advantage
stems from the GPI anchor of DAR Purified DAF can be
reincorporated into cells (11), and this cellular form has
markedly higher activity in inhibiting the C3 convertase than
a soluble form of DAF (18, 19). Thus, one potential approach
wouldbe to treat tissues directly with DAF and allowincor-
poration in the cell membranes. There are many potential
technical difficulties, though one area where it might be easily
applicable is transplantation. Because we have also constructed
a GPI-anchored form of MCP and shown in this study that
it can protect cells from C, both recombinant DAF and MCP-
PI could be used in this manner.
One of the original motivations for this studywas to test
the hypothesis that attachment of a protein to the plasma
membrane by a GPI anchor instead ofa TM region and cyto-
plasmic tail would be advantageous to function. Direct mea-
surements of lateral diffusion constants for DAF (24) and Thy-1
(25) indicated a high lateral mobility for these two GPI-
anchored membrane proteins. This led to the suggestion that
GPI-anchored proteins would have higher lateral mobility than
TM proteins, and because ofthe presumed advantage oflateral
mobility, e.g., in contacting a ligand on the cell or in the
extracellular medium or on another surface, the above hy-
pothesis was advanced. This hypothesis concerningthe func-
tional advantage of a GPI anchor due to increased lateral mo-
bility has been widely cited in reviews (48, 49), yet there has
been no evidence to support (or refute) it. The present study
has shown that GPI and TM versions ofDAF or MCP func-
tion equally well in protecting cellsfrom C3 deposition and
cytotoxicity. An alternative DAFTM construct using a
different TM and cytoplasmic region was also tested and found
to match GPI-anchored DAF in C protection, so this finding
is not a function of a particular TM sequence. There are two
possible ways to interpret this conclusion: either the putative
greater lateral mobility of a GPI-anchored vs. TM protein
does not impart a functional advantage, or else the two ver-
sions of the protein have equivalent lateral mobility. The latter
is really the crux of the matter, for the reports to date simply
measure the lateral mobility of a GPI-anchored protein and
by comparisonwith the whole range for TM proteins or lipids,
suggest that the GPI anchor allows faster lateral mobility.
Clearly, the definitive measurement is to compare GPI and
TM versions of the same protein. It is logical (but unproven)
that faster movement would be advantageous to DAF in con-
tacting C3 convertases. The present results are in fact a func-
tional measurement suggesting equal lateral mobility for GPI
and TM versions of a protein. However, final interpretation
must await direct measurements of the lateral mobility of
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